Febuxostat demonstrates efficacy and renal safety in patients with gout and CKD
Peiyu Zhang et al conducted a study to explore the efficacy and renal safety of febuxostat in gout and stage 2-4 chronic kidney disease (CKD) and factors that correlated with target serum urate (SU).The article has been published in Rheumatology therapy journal.
A single-center retrospective study including male patients with gout and CKD was conducted. SU, the rate of SU < 360 umol/L (RAT), and renal safety were analyzed in subjects who received febuxostat over 44 weeks.
Key findings of the study were:
• 102 patients (stage 2 CKD: n = 27; stage 3 CKD: n = 70; stage 4 CKD: n = 5) were enrolled.
• The SU level reduced significantly over 44 weeks (600.76 ± 95.42 versus 405.52 ± 111.93 umol/ L; P <0.05), and RAT increased to 39.20%.
• The overall estimated glomerular filtration rate (eGFR) level improved over 44 weeks (52.05 ± 11.68 versus 55.46 ± 14.49 mL/min/ 1.73 cm2, p <0.05).
• An obvious improvement of eGFR was observed in stage 3 CKD, in patients with <= 1 risk factor (hypertension, diabetic mellitus, hyperlipidemia, or usage of non-steroidal anti-inflammatory drugs), and in patients with terminal SU <360 umol/L (p <0.05).
• Logistic regression analysis indicated that baseline SU level and body weight were correlated with RAT.
• Patients with SU<600 umol/L and body weight <=70 kg reached higher RAT (56.7%).
The authors concluded that – "In patients with gout and CKD, urate lowering treatment with febuxostat significantly reduces SU levels and could improve renal function. Significant improvement in renal function was achieved in patients with stage 3 CKD, without hypertension, diabetic mellitus, hyperlipidemia, or usage of NSAIDs. A ''treat to target'' therapy with febuxostat could obviously improve renal function. Besides, patients with baseline SU <600 umol/L and body weight B 70 kg were more likely to achieve target SU.
Further reading:
Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study
Peiyu Zhang, Mo Chen et al
Rheumatology Therapy (2022) 9:1421–1434
https://doi.org/10.1007/s40744-022-00480-7
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.